N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=36 The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 2 N=20 An Inflammatory Challenge Using Endotoxin
Alcohol Use Disorder · Inflammatory Response · Craving
Primary: Cue-induced Craving — 4.5004; 7.9081; 4.5004; 5.6178 score on a scale — p=0.036
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
N/A N=15 Human Biological Responses to Low Level Ozone
Environmental Exposure · Nasal Inflammation
Primary: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure From Baseline — -1.02; -6.8 percent PMNs in nasal lavage fluid
Phase 1 N=70 Inflammatory Markers in Trauma Patient Outcomes
Polytrauma
Primary: Length of Hospital Stay — 7; 8 days — p==0.275
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 4 N=72 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Acute Coronary Syndrome
Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=141 Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
Phase 2 N=10 SP16 Inflammatory Response Inhibition Trial
Myocardial Infarction · Inflammation
Primary: Area Under the Curve (AUC) for C-reactive Protein (CRP) — 133 mg*day/L
Phase 2 N=11 Interleukin-1 Trap to Treat Autoinflammatory Diseases
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
N/A N=20 Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
N/A N=17 Regulation of the Release of Inflammatory Mediators From Lung Macrophages.
COPD · Chronic Bronchitis · Emphysema
Primary: Macrophage Activation, TNF-a — 6.1; 3.8; 2.6 ng/ml — p=0.05
N/A N=25 Mechanisms of Insulin Resistance in Humans
Inflammation · Insulin Resistance
Primary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
Phase 2 N=10 Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
Acute Myocardial Infarction
Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L
Phase 1 N=42 Inhibition of Sterile Inflammation by Digoxin
Inflammatory Response
Primary: Lower Levels of Spontaneous Reactive Oxygen Species (ROS) Production
N/A N=190 Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
N/A N=44 Challenging the Inflammatory Response System in Insomnia Disorder
Insomnia
Primary: Inflammatory Response to Physiological Challenge- Change in Plasma Levels of IL-6 — 1.5013; 2.1626; 2.5911; 2.7269 pg/mL
Phase 2 N=18 Biomarkers of Irritant-Induced and Allergic Asthma
Asthma
Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
Phase 4 N=55 Effect IV Ibuprofen and Inflammatory Responses
Gallbladder Disease
Primary: Stress Response Inflammation Markers :Cortisol and C Reactive Protein (CRP) — 173.6; 289.5; 17; 17 pg/mL
N/A N=14 IL-17 Neutrophils in CF Lung Inflammation
Cystic Fibrosis
Primary: Change in Sputum IL-17 Neutrophils — 55; 4 % of neutrophils positive for IL-17